Recent Insights into Interactions of Deferoxamine with Cellular and Plasma Iron Pools: Implications for Clinical Use
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
A bstract: Despite the availability of deferoxamine (DFO) for more than three decades, its rates of interaction with cellular iron pools in different tissues, and the effects of its pharmacokinetics on the interaction with plasma iron pools, remain incompletely understood. The positive charge of DFO, together with the negative resting potential in vertebrate cells, favors cellular uptake, whereas the low lipophilicity and high molecular weight counter this effect. The findings presented suggest a facilitated uptake of DFO into hepatocytes, being several hundred‐fold faster than into red cells. Antibodies that selectively recognize ferrioxamine (FO) show that initial hepatocellular iron chelation is cytosolic, but later transposes to lysosomal and ultimately canalicular compartments. Strong FO staining is visible in myocytes within 4‐8 h after commencing a subcutaneous DFO infusion, indicating effective chelation of myocyte iron. A methodology was developed to study the interaction of DFO and its metabolites with plasma iron pools by stabilizing DFO with aluminum ions, thereby preventing iron shuttling from non‐transferrin‐bound iron (NTBI) onto DFO after plasma collection. DFO removes only about a third of NTBI rapidly, and NTBI is rarely cleared completely. Increasing DFO dosing does not increase NTBI removal, but instead leads to a greater rebound in NTBI on cessation of intravenous infusion. Thus, intermittent infusions of high‐dose DFO are less desirable than continuous infusions at low doses, particularly in high‐risk patients. Here the benefits of continuous DFO on heart function occur before changes in T2*‐visible storage iron, consistent with early removal of a toxic labile iron pool within myocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oudit, G. Y., Sun, H., Trivieri, M. G., Koch, S. E., Dawood, F., Ackerley, C., Yazdanpanah, M., Wilson, G. J., Schwartz, A., Liu, P. P., et al. (2003) · Nature Medicine · doi:10.1038/nm920 · Cited by 480
Cited by
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
An update on iron chelation therapy.
(2012) · Europe PMC (PubMed Central) · doi:10.2450/2012.0008-12 · Cited by 233
Walter, P. B., Macklin, E. A., Porter, J., Evans, P., Kwiatkowski, J. L., Neufeld, E. J., Coates, T., Giardina, P. J., Vichinsky, E., Olivieri, N., et al. (2008) · Haematologica · doi:10.3324/haematol.11755 · Cited by 87
“NTBI has been suggested to be toxic to the heart and other iron-susceptible tissues.(8,9) Deferasirox (ICL670, Exjade®, Novartis) is an orally administered tridentate iron chelator with a relatively long circulating half-life of 8 to 16 hours(10,11) and documented cellular permeability.”
BackgroundSelf-citationTetrahydrobiopterin, superoxide, and vascular dysfunction
Vásquez-Vivar, J. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.07.024 · Cited by 84
“It is recognized that enhanced iron mobilization and storage is associated with endothelial dysfunction and progression of vascular diseases [103].”
Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes: Recent Developments
Leitch, H. A. (2011) · Drugs · doi:10.2165/11585280-000000000-00000 · Cited by 17
Metadata
- Authors
- PORTER, J. B., RAFIQUE, R., SRICHAIRATANAKOOL, S., DAVIS, B. A., SHAH, F. T., HAIR, T., & EVANS, P.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2005-11
- Volume
- 1054
- Issue
- 1
- Pages
- 155-168
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2027345480
- Cited by
- 80
- References
- 1
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Insights into Interactions of Deferoxamine with Cellular and Plasma Iron Pools: Implications for Clinical Use. https://app.cochat.ai/papers/10.1196/annals.1345.018
- The paper
- PORTER, J. B., RAFIQUE, R., SRICHAIRATANAKOOL, S., DAVIS, B. A., SHAH, F. T., HAIR, T., & EVANS, P. (2005). Recent Insights into Interactions of Deferoxamine with Cellular and Plasma Iron Pools: Implications for Clinical Use. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1345.018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.